Archive 1995–2023
2008, volume 24, issue 4
Review article
Clinical methods of glutamatergic NMDA receptor modulation in treating schizophrenia
Farmakoterapia w Psychiatrii i Neurologii, 2008, 4, 243–248
Keywords: glycine, D-serine, D-cycloserine, glycine transporter, sarkosine, NMDA, schizophrenia
Summary
Article describes clinical possibilities of glutamatergic NMDA receptor modulation in schizophrenia. Clinical trials indicate that glycine site agonists of the NMDA receptor (glycine, D-serine, D-cycloserine, D-alanine) or glycine transporter inhibitors (sarcosine) may moderately (ca. 10-20%) reduce negative symptoms when used as adjuvants to antipsychotics but with exception of clozapine. Treatment is well-tolerated, frequency of signifi cant side effect is similar as in placebo groups.
Correspondence address
Dominik Strzelecki
Klinika Zaburzeń Afektywnych i Psychotycznych
Uniwersytetu Medycznego
ul. Czechosłowacka 8/10, 92-216 Łódź
tel. 042 675 72 13
e-mail: [email]strzeleckidomin@poczta.onet.pl[/email]
Klinika Zaburzeń Afektywnych i Psychotycznych
Uniwersytetu Medycznego
ul. Czechosłowacka 8/10, 92-216 Łódź
tel. 042 675 72 13
e-mail: [email]strzeleckidomin@poczta.onet.pl[/email]